PGs2_5730494M16Rik inhibitors represent a class of chemical compounds primarily identified for their ability to selectively modulate the activity of the PGs2_5730494M16Rik gene or protein product, which is involved in a variety of cellular processes. These inhibitors are characterized by their specificity in targeting the enzymatic or binding domains associated with the PGs2_5730494M16Rik-related pathways. Chemically, these inhibitors may exhibit structural diversity, incorporating various functional groups such as aromatic rings, heterocyclic cores, and electron-donating or withdrawing substituents that allow precise interactions with their molecular target. The mode of action for these inhibitors often involves direct binding to the active or allosteric sites of the protein encoded by the PGs2_5730494M16Rik gene, resulting in a modulation of its activity at the molecular level. This, in turn, influences the downstream biochemical reactions and cellular processes governed by the protein.
From a biochemical perspective, PGs2_5730494M16Rik inhibitors are of interest due to their ability to affect the signaling cascades and enzymatic reactions linked to this gene. The inhibitors can vary in their affinity and selectivity, with some acting as reversible competitive inhibitors, while others may irreversibly bind to the target site, leading to prolonged modulation. Researchers often study the molecular interactions between these inhibitors and the PGs2_5730494M16Rik protein to understand the structure-activity relationships (SAR), which help refine the design of more effective inhibitors. Through various analytical techniques such as X-ray crystallography, molecular docking, and spectroscopic methods, the binding conformations and interaction profiles of PGs2_5730494M16Rik inhibitors are elucidated, offering deeper insight into their roles in cellular and molecular biology.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A inhibits histone deacetylase, which may lead to changes in chromatin structure and potentially suppress the expression of genes such as TTLL2. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This compound incorporates into DNA and RNA, inhibiting DNA methyltransferase, which could result in the hypomethylation of the TTLL2 gene promoter and its reduced expression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat, by inhibiting histone deacetylases, can alter gene expression profiles including potentially decreasing TTLL2 expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A binds to G-C rich DNA sequences, possibly preventing transcription factors from binding to the TTLL2 promoter region and inhibiting its expression. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D intercalates into DNA, inhibiting RNA polymerase and potentially downregulating TTLL2 mRNA synthesis. | ||||||
Histone Lysine Methyltransferase Inhibitor Inhibitor | 935693-62-2 (free base) | sc-202651 | 5 mg | $151.00 | 4 | |
BIX-01294 inhibits G9a histone methyltransferase, possibly affecting chromatin states and reducing TTLL2 gene expression. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG108, as a DNA methyltransferase inhibitor, may decrease methylation at the TTLL2 promoter, leading to its reduced expression. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Decitabine is incorporated into DNA and inhibits methylation, which could result in decreased TTLL2 expression by altering promoter methylation status. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium Butyrate acts as a histone deacetylase inhibitor, potentially leading to altered acetylation patterns and downregulation of TTLL2. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
Entinostat selectively inhibits class I histone deacetylases, which may impact gene expression patterns including TTLL2 expression. | ||||||